Parkinsonism & related disorders最新文献

{"title":"Involvement of the basal forebrain and hippocampus in memory deficits in Parkinson's disease","authors":"Haruhi Sakamaki-Tsukita ,&nbsp;Atsushi Shima ,&nbsp;Daisuke Kambe ,&nbsp;Koji Furukawa ,&nbsp;Akira Nishida ,&nbsp;Ikko Wada ,&nbsp;Kenji Yoshimura ,&nbsp;Yusuke Sakato ,&nbsp;Yuta Terada ,&nbsp;Hodaka Yamakado ,&nbsp;Yosuke Taruno ,&nbsp;Etsuro Nakanishi ,&nbsp;Masanori Sawamura ,&nbsp;Yasutaka Fushimi ,&nbsp;Tomohisa Okada ,&nbsp;Yuji Nakamoto ,&nbsp;Laszlo Zaborszky ,&nbsp;Ryosuke Takahashi ,&nbsp;Nobukatsu Sawamoto","doi":"10.1016/j.parkreldis.2024.107134","DOIUrl":"10.1016/j.parkreldis.2024.107134","url":null,"abstract":"<div><h3>Introduction</h3><p>Magnetic resonance imaging (MRI)-determined atrophy of the nucleus basalis of Meynert (Ch4) predicts cognitive decline in Parkinson's disease (PD). However, interactions with other brain regions causing the decline remain unclear. This study aimed to describe how MRI-determined Ch4 atrophy leads to cognitive decline in patients with PD.</p></div><div><h3>Methods</h3><p>We evaluated 137 patients with PD and 39 healthy controls using neuropsychological examinations, MRI, and ¹²³I-ioflupane single-photon emission computed tomography. First, we explored brain areas with regional gray matter loss correlated with Ch4 volume reduction using voxel-based morphometry (VBM). We then assessed the correlation between Ch4 volume reduction and cognitive impairments in PD using partial correlation coefficients (r_par). Finally, we examined whether the regional gray matter loss mediated the association between Ch4 volume reduction and cognitive impairments using mediation analysis.</p></div><div><h3>Results</h3><p>Our PD cohort was “advanced-stage enriched.” VBM analyses revealed that Ch4 volume loss was correlated with volume reduction in the medial temporal lobe in PD (P &lt; 0.05, family-wise error corrected, &gt;29 voxels). Ch4 volume reduction was significantly correlated with verbal memory deficits in PD when adjusted for age, sex, total brain volume, and ¹²³I-ioflupane uptake in the caudate (r_par = 0.28, P &lt; 0.001). The mediation analysis revealed that the hippocampus mediated the effects of Ch4 volumes on verbal memory (average causal mediation effect = 0.013, 95 % CI = 0.006–0.020, P &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>Particularly in advanced-stage PD, Ch4 atrophy was associated with medial temporal lobe atrophy, which played an intermediary role in the relationship between Ch4 atrophy and verbal memory impairments.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107134"},"PeriodicalIF":3.1,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1353802024011465/pdfft?md5=b79168105d43a3434ed339edbd21cd44&pid=1-s2.0-S1353802024011465-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prominent loss of striatal dopamine transporter binding in frontotemporal lobar degeneration with the MAPT N279K mutation present as early as at prodromal stage without parkinsonism","authors":"Toji Miyagawa,&nbsp;Cynthia Vernon,&nbsp;Scott A. Przybelski,&nbsp;Paul H. Min,&nbsp;Julie A. Fields,&nbsp;Bradford C. Dickerson,&nbsp;Dennis W. Dickson,&nbsp;Kejal Kantarci,&nbsp;Val J. Lowe,&nbsp;Zbigniew K. Wszolek,&nbsp;Bradley F. Boeve","doi":"10.1016/j.parkreldis.2024.107144","DOIUrl":"10.1016/j.parkreldis.2024.107144","url":null,"abstract":"<div><p>Our research found out, from ¹²³I-FP-CIT SPECT scans of three familial frontotemporal dementia (fFTD) individuals with <em>MAPT</em> N279K mutation and similar autopsy findings of frontotemporal degeneration with severe neuronal loss in the substantia nigra, that prominent decrease of dopamine transporter binding (z-score &lt; −5.0) was present at prodromal fFTD without parkinsonism.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107144"},"PeriodicalIF":3.1,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study","authors":"Violetta Rozani ,&nbsp;Miri Glikshtein Bezimianski ,&nbsp;Joseph Azuri ,&nbsp;Michal Bitan ,&nbsp;Chava Peretz","doi":"10.1016/j.parkreldis.2024.107132","DOIUrl":"10.1016/j.parkreldis.2024.107132","url":null,"abstract":"<div><h3>Background</h3><p>Emerging evidence suggests a potential association between certain anti-diabetic drugs and a reduced risk of Parkinson's disease (PD). Limited population-based studies have investigated users of newer anti-diabetic drugs such as GLP-1 agonists or SGLT2 inhibitors.</p></div><div><h3>Objective</h3><p>The aim of this study was to assess the risk of PD among individuals with type 2 diabetes mellitus (T2DM) who were treated with various types of anti-diabetic drugs over time.</p></div><div><h3>Methods</h3><p>A population-based cohort comprising T2DM patients aged over 30 who used metformin, GLP-1 agonists, thiazolidinediones, sulfonylureas, DPP4 inhibitors, SGLT2 inhibitors, or meglitinides between January 1, 1999 and December 31, 2018. Data were obtained between the diabetes registration and drug purchase databases of Maccabi Healthcare Services. Time-dependent Cox regression models, adjusted for sex, age, and comorbidities were employed to calculate the adjusted hazard ratios (HRs) for the PD risk associated with different anti-diabetic drugs over time.</p></div><div><h3>Results</h3><p>The study population comprised 86,229 T2DM patients, with 53.9 % males. The mean age at the first anti-diabetic drug purchase was 59.0 ± 11.0 and 62.0 ± 11.0 years for men and women respectively. Compared to metformin, several drug types were associated with a significantly lower PD risk: thiazolidinediones (HR = 0.91, 95 % CI:0.074–1.14); DPP4 inhibitors (HR = 0.60, 95 % CI:0.53–0.67); meglitinides (HR = 0.63, 95 % CI:0.53–0.74); GLP-1 agonists (HR = 0.54, 95 % CI:0.39–0.73); and SGLT2 inhibitors (HR = 0.15, 95 % CI:0.10–0.21).</p></div><div><h3>Conclusions</h3><p>Our results suggest a reduced risk of PD with certain anti-diabetic drugs, particularly SGLT2 inhibitors and GLP-1 agonists. Validation through extensive big-data studies is essential to confirm these results and to optimize PD prevention and management.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107132"},"PeriodicalIF":3.1,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1353802024011441/pdfft?md5=0e94c36bf60886f86ebaf635cec0e22c&pid=1-s2.0-S1353802024011441-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quick MSA-QoL: A validated, abbreviated health-related quality of life questionnaire for use in Multiple System Atrophy","authors":"D. Jugnarain,&nbsp;A. Schrag","doi":"10.1016/j.parkreldis.2024.107143","DOIUrl":"10.1016/j.parkreldis.2024.107143","url":null,"abstract":"<div><h3>Background</h3><p>Health-related quality of life is an important patient-reported outcome, which can be assessed using instruments such as the Multiple System Atrophy (MSA) Quality of Life (MSA-QoL) scale. However, at 40-items its length can prove burdensome, particularly to patients with a disease such as MSA. This can contribute to respondent burden and poor-quality response data.</p></div><div><h3>Objective</h3><p>The objective of this study was to develop an abbreviated MSA-QoL scale for use in clinical practise and trials (Quick MSA-QoL).</p></div><div><h3>Methods</h3><p>A single-factor 15-item scale was developed with data from 310 patients with MSA, using exploratory factor analysis (EFA). A separate dataset (n = 279) was used for analysis of psychometric properties and for confirmatory factor analysis.</p></div><div><h3>Results</h3><p>Missing data was minimal, with even distribution of scores and negligible floor/ceiling effects (0/0.4%). Reliability was high (Cronbach alpha 0.870, test-retest reliability 0.950). Good item-total scale correlations were observed (r = 0.402–0.618), and the overall scale correlated well with other validated questionnaires including the original MSA-QoL (r = 0.862). Confirmatory factor analysis demonstrated acceptable model fit indices. Responsiveness data from re-administration of the Quick MSA-QoL 10 months from baseline testing found the overall scale to be sensitive to change.</p></div><div><h3>Conclusions</h3><p>These data suggest that the Quick MSA-QoL is a suitable and efficient scale for use in clinical trials, minimising respondent burden and maintaining data quality.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107143"},"PeriodicalIF":3.1,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1353802024011556/pdfft?md5=7c15fc51c84f9e5fae14d6069dce3388&pid=1-s2.0-S1353802024011556-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between cigarette smoking and dementia with Lewy bodies","authors":"Anna E. Goodheart ,&nbsp;Stephen N. Gomperts","doi":"10.1016/j.parkreldis.2024.107133","DOIUrl":"10.1016/j.parkreldis.2024.107133","url":null,"abstract":"<div><h3>Introduction</h3><p>Cigarette smoking is associated with a reduced risk of Parkinson's disease (PD). As dementia with Lewy bodies (DLB) and PD share core neuropathologic features, we set out to examine the relationship between smoking and DLB.</p></div><div><h3>Methods</h3><p>Diagnosis at baseline visit and smoking history of participants ≥50 years old in the National Alzheimer's Coordinating Center (NACC) cohort were evaluated in this cross-sectional study. Odds of diagnosis of cognitive impairment due to DLB, PD, vascular dementia (VD), or Alzheimer's disease (AD) compared to normal cognition based on smoking status and duration were determined using logistic regression.</p></div><div><h3>Results</h3><p>37,478 participants were included (mean age 72 years (SD 9), 57 % female). The odds of DLB were reduced in all smoking status groups compared to never smokers (OR (95 % CI)): ever smokers 0.850 (0.745–0.971), former smokers 0.871 (0.761–0.997), current smokers 0.640 (0.419–0.947)) and in all smoking duration groups. As expected, the odds of PD were reduced in all smoking groups and fell with longer smoking duration. The odds of VD were increased in the current smoking group and rose with greater smoking duration. The odds of AD were unchanged in current smokers, decreased in ever and former smokers, and increased with longer cumulative smoking duration.</p></div><div><h3>Conclusions</h3><p>Cigarette smoking is associated with lower odds of diagnosis of DLB at baseline visit in the NACC cohort. In the context of the well-established reduced risk of PD among smokers, this preliminary evidence of a potential protective effect of smoking on DLB warrants further study.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107133"},"PeriodicalIF":3.1,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total physical activity, plant-based diet and neurodegenerative diseases: A prospective cohort study of the UK biobank","authors":"Xiaoting Zheng,&nbsp;Jiyong Liu,&nbsp;Shichan Wang,&nbsp;Yi Xiao,&nbsp;Qirui Jiang,&nbsp;Chunyu Li,&nbsp;Huifang Shang","doi":"10.1016/j.parkreldis.2024.107125","DOIUrl":"10.1016/j.parkreldis.2024.107125","url":null,"abstract":"<div><h3>Introduction</h3><p>Neurodegenerative diseases (NDDs) result from a complex interplay of genetic, environmental and aging factors. A balanced diet and adequate physical activity (PA) are recognized as pivotal components among modifiable environmental factors. The independent impact on NDD incidence has been previously debated. This investigation seeks to delineate the association between PA and NDDs across various levels of adherence to a plant-based diet.</p></div><div><h3>Methods</h3><p>In this study, a cohort of 368,934 participants from the UK Biobank was analyzed. Total physical activity (TPA) levels and healthful plant-based diet index (hPDI) were calculated and categorized. A multiple adjusted Cox model was utilized to evaluate the influence of TPA and hPDI on common NDDs, respectively.</p></div><div><h3>Results</h3><p>Finally, 4602 identified cases diagnosed as Alzheimer's disease (AD), Parkinson's disease (PD) or amyotrophic lateral sclerosis (ALS). We found that higher TPA was significantly associated with a reduced risk of developing AD (Q3: HR 0.87; Q4: HR 0.78) and PD (Q3: HR 0.86; Q4: HR 0.81). The protective effect was further accentuated with adherence to a plant-based diet. However, these connections were not observed in the analysis of ALS regardless of dietary patterns.</p></div><div><h3>Conclusion</h3><p>Our findings underscore a significant association between higher TPA and reduced risks of AD and PD, with an enhanced effect observed in conjunction with a plant-based diet. This study contributes to addressing the knowledge gap regarding the combined impact of TPA and a plant-based diet on NDDs occurrence, providing insights into potential underlying mechanisms.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107125"},"PeriodicalIF":3.1,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1353802024011374/pdfft?md5=7c263b9f3ebe8a99e970c29366c3bebe&pid=1-s2.0-S1353802024011374-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Living with Parkinson's disease in Portugal: Findings from PRISM study","authors":"Helena C. Brigas ,&nbsp;Ana Margarida Rodrigues ,&nbsp;Ana Morgadinho ,&nbsp;Miguel F. Gago ,&nbsp;Rita M. Simões","doi":"10.1016/j.parkreldis.2024.107124","DOIUrl":"10.1016/j.parkreldis.2024.107124","url":null,"abstract":"<div><h3>Background</h3><p>Parkinson's disease (PD) ranks second in global neurodegenerative disorders. The “Parkinson's Real-world Impact assesSMent (PRISM)” study addressed the disease burden and treatment of European PD patients. Yet, the burden on Portuguese PD patients remains unexplored. Here, we outline the demographics, clinical features, and impact of PD in the Portuguese PRISM cohort.</p></div><div><h3>Methods</h3><p>Descriptive analysis of the PRISM Portuguese cohort (80 patients) was performed, emphasizing socio-demographic data, anti-PD medication usage, PD impact on patients' lives and healthcare resources utilization.</p></div><div><h3>Results</h3><p>The predominant comorbidities in the Portuguese PD cohort (55 % male; mean age 66.2 years; mean disease duration 8.8 years) included depression (26.3 %) and anxiety (26.3 %). Levodopa was the initial prescribed anti-PD medication for 88 % of patients. Among Portuguese PDP, dopamine agonists (DA), monoamine oxidase-B (MAO-B) inhibitors, and catechol-O-methyltransferase (COMT) inhibitors were used by 50 %, 44.4 %, and 18.3 %, respectively. Portuguese PDP experienced impaired quality of life (PDQ-39 score: 31.3 ± 16.8), various non-motor symptoms, namely sadness/blues (65.4 %), urinary urgency (63.5 %), high/low sex interest (57.7 %), while 56 % reported at least one impulse control behavior. Additionally, 30.8 % retired early due to PD and 31.8 % reduced hours in daily activities. Mental health appointments were attended by 31 %, primarily in psychiatry (19 %) and psychology (6 %), and psychotherapy.</p></div><div><h3>Conclusion</h3><p>This study uncovers the burden of PD among Portuguese patients, revealing current treatment methods, impact on daily life and healthcare resources employed in Portugal. It emphasizes the need for personalized clinical strategies at national and international levels to improve long-term health outcomes and quality of life of PD patients.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107124"},"PeriodicalIF":3.1,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142135862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurovascular conflict in primary hemifacial spasm: A radiological topographic and severity assessment of contact","authors":"D.D.S. Anudeep,&nbsp;K. Karthik,&nbsp;Vikram V. Holla,&nbsp;Nitish Kamble,&nbsp;Ravi Yadav,&nbsp;Pramod Kumar Pal,&nbsp;Rohan R. Mahale","doi":"10.1016/j.parkreldis.2024.107130","DOIUrl":"10.1016/j.parkreldis.2024.107130","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107130"},"PeriodicalIF":3.1,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hope vs. Hype III: Rescue/on-demand therapies are preferable to device-assisted therapies in Parkinson disease","authors":"","doi":"10.1016/j.parkreldis.2024.106079","DOIUrl":"10.1016/j.parkreldis.2024.106079","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"126 ","pages":"Article 106079"},"PeriodicalIF":3.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1353802024000919/pdfft?md5=40c4feba501bd47fd93e732a26336253&pid=1-s2.0-S1353802024000919-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140089578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid disease and cervical dystonia","authors":"","doi":"10.1016/j.parkreldis.2024.106082","DOIUrl":"10.1016/j.parkreldis.2024.106082","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"126 ","pages":"Article 106082"},"PeriodicalIF":3.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}